Sarcoma

Sarcoma / 2003 / Article

Case Report | Open Access

Volume 7 |Article ID 791457 | https://doi.org/10.1080/1357714031000114165

C. L. M. H. Gibbons, M. Petra, R. Smith, N. A. Athanasou, "Bisphosphonate Treatment of Benign Multifocal and Unifocal Osteolytic Tumours of Bone", Sarcoma, vol. 7, Article ID 791457, 7 pages, 2003. https://doi.org/10.1080/1357714031000114165

Bisphosphonate Treatment of Benign Multifocal and Unifocal Osteolytic Tumours of Bone

Abstract

Growth of benign tumours and tumour-like lesions of bone results in osteolysis which may cause pathological fracture. Bisphosphonates are anti-osteolytic agents which have proved effective in the treatment of number of osteolytic conditions. In this study we report the results of treatment with the aminobisphosphonate, pamidronate, of three benign osteolytic tumours of bone, two cases of fibrous dysplasia and one of Langerhans cell histiocytosis. In all three cases there was clinical and radiological improvement following treatment. Radiologically, bone lesions did not exhibit progressive enlargement. Two cases of fibrous dysplasia also showed features suggestive of increased bone formation. These findings indicate that bisphosphonates are likely to be useful in controlling the osteolysis of benign tumours/tumour-like lesions of bone, particularly in those cases where surgical intervention is not possible or multifocal lesions are present.

Copyright © 2003 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views99
Downloads610
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.